Get the Stockscreener App
11.88
2.22%
-0.27
After Hours:
11.88
Nurix Therapeutics Inc stock is traded at $11.88, with a volume of 1.35M.
It is down -2.22% in the last 24 hours and down -23.11% over the past month.
See More
Previous Close:
$12.15
Open:
$11.82
24h Volume:
1.35M
Relative Volume:
1.83
Market Cap:
$952.38M
Revenue:
$54.55M
Net Income/Loss:
$-193.57M
P/E Ratio:
-4.1107
EPS:
-2.89
Net Cash Flow:
$-181.86M
1W Performance:
-10.94%
1M Performance:
-23.11%
6M Performance:
-47.13%
1Y Performance:
-19.18%
1-Day Range:
$11.38
$12.03
1-Week Range:
$11.38
$13.54
52-Week Range:
$11.38
$29.56
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Name
Nurix Therapeutics Inc
Sector
Industry
Phone
(415) 660-5320
Address
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Compare NRIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
11.88 | 952.38M | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-25 | Initiated | Leerink Partners | Market Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-11-24 | Initiated | Jefferies | Buy |
| Sep-06-24 | Resumed | Robert W. Baird | Outperform |
| Jul-31-24 | Initiated | Truist | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-09-23 | Initiated | Barclays | Overweight |
| Feb-28-23 | Initiated | Oppenheimer | Outperform |
| Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Dec-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-30-21 | Resumed | Piper Sandler | Overweight |
| Apr-30-21 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Nov-19-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | Stifel | Buy |
View All
Nurix Therapeutics Inc Stock (NRIX) Latest News
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Verastem (NASDAQ:VSTM) versus Nurix Therapeutics (NASDAQ:NRIX) Head-To-Head Analysis - Defense World
Proficio Capital Partners LLC Takes Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Position Boosted by Charles Schwab Investment Management Inc. - MarketBeat
Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting - The Manila Times
Nurix Therapeutics Announces Multiple Presentations At The American Association For Cancer Research (AACR) 2025 Annual Meeting - MarketScreener
Revolutionary AI Platform Drives 4 Cancer Drug Innovations: Nurix AACR 2025 Spotlight - Stock Titan
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Down 6.2%Here's What Happened - MarketBeat
Q3 Earnings Estimate for NRIX Issued By Leerink Partnrs - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Raised to "Hold" at Leerink Partnrs - MarketBeat
Victory Capital Management Inc. Buys 38,672 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Q1 Earnings Estimate for NRIX Issued By Leerink Partnrs - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Up 4.4%Should You Buy? - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely - simplywall.st
Nikko Asset Management Americas Inc. Acquires 236,620 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Now Covered by Analysts at Leerink Partners - MarketBeat
Primecap Management Co. CA Has $4.37 Million Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Upgraded at Leerink Partnrs - Defense World
Victory Capital Management Inc. Increases Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Nurix Therapeutics (NASDAQ:NRIX) Shares Down 6.9%What's Next? - MarketBeat
Beyond The Numbers: 8 Analysts Discuss Nurix Therapeutics Stock - Benzinga
Nurix Therapeutics gets 'market perform' rating as Leerink starts coverage - TradingView
Leerink Partners Initiates Coverage of Nurix Therapeutics (NRIX) with Market Perform Recommendation - Nasdaq
Nurix Therapeutics' Bexobrutideg Gets Orphan Drug Designation For Waldenstrm Macroglobulinemia - Nasdaq
Nurix Therapeutics' Blood Cancer Drug Candidate Gets FDA Orphan Drug Designation - Marketscreener.com
Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia - The Manila Times
Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of - EIN News
Nurix Therapeutics grants stock options to new hires By Investing.com - Investing.com Australia
Nurix Therapeutics grants stock options to new hires - Investing.com India
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Nurix Therapeutics expands board with oncology veteran By Investing.com - Investing.com Australia
Nurix Therapeutics expands board with oncology veteran - Investing.com India
Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors - The Manila Times
Keytruda Developer Roy Baynes Strengthens Nurix Board in Strategic Move - StockTitan
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Candriam S.C.A. - MarketBeat
Nurix Therapeutics Inc Stock (NRIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):